Sanofi Stock Net Income
| SNYNF Stock | USD 96.86 2.70 2.87% |
As of the 9th of February, Sanofi has the Coefficient Of Variation of (4,289), risk adjusted performance of (0.01), and Variance of 2.98. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sanofi, as well as the relationship between them. Please validate Sanofi market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Sanofi is priced more or less accurately, providing market reflects its prevalent price of 96.86 per share. Given that Sanofi has information ratio of (0.08), we advise you to double-check Sanofi's current market performance to make sure the company can sustain itself at a future point.
Sanofi's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Sanofi's valuation are provided below:Sanofi does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Sanofi |
Sanofi 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Sanofi's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Sanofi.
| 11/11/2025 |
| 02/09/2026 |
If you would invest 0.00 in Sanofi on November 11, 2025 and sell it all today you would earn a total of 0.00 from holding Sanofi or generate 0.0% return on investment in Sanofi over 90 days. Sanofi is related to or competes with Novartis, AstraZeneca PLC, GlaxoSmithKline PLC, Roche Holding, Bristol Myers, Sanofi ADR, and Bayer AG. Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic ... More
Sanofi Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Sanofi's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Sanofi upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 8.58 | |||
| Value At Risk | (3.28) | |||
| Potential Upside | 2.87 |
Sanofi Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sanofi's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Sanofi's standard deviation. In reality, there are many statistical measures that can use Sanofi historical prices to predict the future Sanofi's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.07) |
Sanofi February 9, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.06) | |||
| Mean Deviation | 1.14 | |||
| Coefficient Of Variation | (4,289) | |||
| Standard Deviation | 1.73 | |||
| Variance | 2.98 | |||
| Information Ratio | (0.08) | |||
| Jensen Alpha | (0.10) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | (0.07) | |||
| Maximum Drawdown | 8.58 | |||
| Value At Risk | (3.28) | |||
| Potential Upside | 2.87 | |||
| Skewness | (0.17) | |||
| Kurtosis | 1.24 |
Sanofi Backtested Returns
Sanofi owns Efficiency Ratio (i.e., Sharpe Ratio) of -0.0476, which indicates the firm had a -0.0476 % return per unit of risk over the last 3 months. Sanofi exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please validate Sanofi's Variance of 2.98, risk adjusted performance of (0.01), and Coefficient Of Variation of (4,289) to confirm the risk estimate we provide. The entity has a beta of 0.67, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sanofi's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sanofi is expected to be smaller as well. At this point, Sanofi has a negative expected return of -0.0791%. Please make sure to validate Sanofi's treynor ratio, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Sanofi performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.42 |
Average predictability
Sanofi has average predictability. Overlapping area represents the amount of predictability between Sanofi time series from 11th of November 2025 to 26th of December 2025 and 26th of December 2025 to 9th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Sanofi price movement. The serial correlation of 0.42 indicates that just about 42.0% of current Sanofi price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.42 | |
| Spearman Rank Test | 0.42 | |
| Residual Average | 0.0 | |
| Price Variance | 4.04 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Sanofi reported net income of 6.72 B. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The net income for all United States stocks is significantly lower than that of the firm.
Sanofi Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Sanofi's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Sanofi could also be used in its relative valuation, which is a method of valuing Sanofi by comparing valuation metrics of similar companies.Sanofi is currently under evaluation in net income category among its peers.
Sanofi Fundamentals
| Return On Equity | 0.0959 | |||
| Return On Asset | 0.0607 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.26 % | |||
| Current Valuation | 135.37 B | |||
| Shares Outstanding | 1.25 B | |||
| Shares Owned By Insiders | 11.23 % | |||
| Shares Owned By Institutions | 46.69 % | |||
| Price To Earning | 7.73 X | |||
| Price To Book | 1.60 X | |||
| Price To Sales | 2.73 X | |||
| Revenue | 45.39 B | |||
| Gross Profit | 31.69 B | |||
| EBITDA | 10.76 B | |||
| Net Income | 6.72 B | |||
| Cash And Equivalents | 6.9 B | |||
| Cash Per Share | 5.51 X | |||
| Total Debt | 14.86 B | |||
| Debt To Equity | 0.30 % | |||
| Current Ratio | 1.30 X | |||
| Book Value Per Share | 58.33 X | |||
| Cash Flow From Operations | 10.52 B | |||
| Earnings Per Share | 5.77 X | |||
| Price To Earnings To Growth | 1.63 X | |||
| Target Price | 123.28 | |||
| Number Of Employees | 58 | |||
| Beta | 0.41 | |||
| Market Capitalization | 120.25 B | |||
| Total Asset | 124.58 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 3.83 % | |||
| Net Asset | 124.58 B | |||
| Last Dividend Paid | 3.56 |
About Sanofi Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Sanofi's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sanofi using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sanofi based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in Sanofi Pink Sheet
Sanofi financial ratios help investors to determine whether Sanofi Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Sanofi with respect to the benefits of owning Sanofi security.